Beat Childhood Cancer offers phase I and phase II clinical trials to children battling childhood cancer. Our focus is on using precision medicine in patients at diagnosis as well as in difficult to treat relapsed and refractory cancers. Our goal is to increase survival and decrease toxicity while targeting the unique factors driving each child’s tumor.


NMTRC006B – An Intermediate Expanded Use Trial of DFMO – Study Record |

NMTRC012 – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) – Study Record |

NMTRC014 – Neuroblastoma Maintenance Therapy Trial (NMTT) – Study Record |

BCC015 – EFlornithine (DFMO) and Etoposide for Relapsed/ Refractory Neuroblastoma – Study Record |

BCC016 – DFMO as Maintenance Therapy for Molecular High/ Very High Risk and Relapsed Medulloblastoma – Study Record |

BCC017 – PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH) – Study Record |

BCC018 – Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma – Study Record |

BCC-BIO-001 – Beat Childhood Cancer Specimen Banking and Data Registry – Study Record |

BCC020 – A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas – Study Record |

Coming soon in 2024 BCC021, and BCC022!